{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T21:51:46Z","timestamp":1725918706482},"reference-count":92,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2005,5,1]],"date-time":"2005-05-01T00:00:00Z","timestamp":1114905600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medical Clinics of North America"],"published-print":{"date-parts":[[2005,5]]},"DOI":"10.1016\/j.mcna.2004.12.002","type":"journal-article","created":{"date-parts":[[2005,4,18]],"date-time":"2005-04-18T14:53:11Z","timestamp":1113835991000},"page":"511-523","source":"Crossref","is-referenced-by-count":7,"title":["Multiple Risk Factor Intervention in Chronic Kidney Disease: Management of Cardiac Disease in Chronic Kidney Disease Patients"],"prefix":"10.1016","volume":"89","author":[{"given":"Bryan M.","family":"Curtis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adeera","family":"Levin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick S.","family":"Parfrey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.mcna.2004.12.002_bib1","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1097\/01.ASN.0000014251.87778.01","article-title":"Cumulative risk for developing end-stage renal disease in the US population","volume":"13","author":"Kiberd","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.mcna.2004.12.002_bib2","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1046\/j.1523-1755.1999.00773.x","article-title":"Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency","volume":"56","author":"Culleton","year":"1999","journal-title":"Kidney Int"},{"issue":"12 Suppl","key":"10.1016\/j.mcna.2004.12.002_bib3","first-page":"S16","article-title":"Epidemiology of cardiovascular disease in chronic renal disease","volume":"9","author":"Foley","year":"1998","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.mcna.2004.12.002_bib4","first-page":"455","article-title":"Cost analysis of dialysis treatments for end-stage renal disease (ESRD)","volume":"18","author":"Goeree","year":"1995","journal-title":"Clin Invest Med"},{"key":"10.1016\/j.mcna.2004.12.002_bib5","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1053\/ajkd.2002.34924","article-title":"Cost analysis of ongoing care of patients with end-stage renal disease: the impact of dialysis modality and dialysis access","volume":"40","author":"Lee","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.mcna.2004.12.002_bib6","series-title":"USRDS 2003 annual data report: atlas of end-stage renal disease in the United States","author":"US Renal Data System","year":"2003"},{"key":"10.1016\/j.mcna.2004.12.002_bib7","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1053\/ajkd.2001.24520","article-title":"Prevalence and characteristics of individuals with chronic kidney disease in a large health maintenance organization","volume":"37","author":"Nissenson","year":"2001","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.mcna.2004.12.002_bib8","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1097\/01.ASN.0000013291.78621.26","article-title":"Prevalence of low glomerular filtration rate in nondiabetic Americans: Third National Health and Nutrition Survey (NHANES III)","volume":"13","author":"Clase","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.mcna.2004.12.002_bib9","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1046\/j.1523-1755.2002.00299.x","article-title":"Methodological issues in studying the epidemiology of mild to moderate chronic renal insufficiency","volume":"61","author":"Hsu","year":"2002","journal-title":"Kidney Int"},{"key":"10.1016\/j.mcna.2004.12.002_bib10","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1001\/archinte.159.15.1785","article-title":"Prevalence and correlates of elevated serum creatinine levels","volume":"159","author":"Culleton","year":"1999","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.mcna.2004.12.002_bib11","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1001\/archinte.161.9.1207","article-title":"Prevalence of high blood pressure and elevated serum creatinine level in the United States: findings from the Third National Health and Nutrition Examination Survey (1988\u20131994)","volume":"161","author":"Coresh","year":"2001","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.mcna.2004.12.002_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1053\/ajkd.2003.50007","article-title":"Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey","volume":"41","author":"Coresh","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.mcna.2004.12.002_bib13","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1056\/NEJM199403313301301","article-title":"The effects of dietary protein restriction and blood pressure control on the progression of chronic renal disease","volume":"330","author":"Klahr","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1016\/j.mcna.2004.12.002_bib14","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1038\/ki.1997.260","article-title":"Predictors of the progression of renal disease in the Modification of Diet in Renal Disease Study","volume":"51","author":"Hunsicker","year":"1997","journal-title":"Kidney Int"},{"key":"10.1016\/j.mcna.2004.12.002_bib15","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1053\/ajkd.2001.26850","article-title":"Epidemiological evaluation of known and suspected cardiovascular risk factors in chronic renal impairment","volume":"38","author":"Landray","year":"2001","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.mcna.2004.12.002_bib16","doi-asserted-by":"crossref","first-page":"327","DOI":"10.5414\/CNP57327","article-title":"Cardiovascular disease risk factors in chronic renal insufficiency","volume":"57","author":"Sarnak","year":"2002","journal-title":"Clin Nephrol"},{"issue":"6 Suppl 3","key":"10.1016\/j.mcna.2004.12.002_bib17","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1053\/ajkd.2000.19926","article-title":"Chronic renal insufficiency: current understandings and their implications","volume":"36","author":"Bolton","year":"2000","journal-title":"Am J Kidney Dis"},{"issue":"4 Suppl 1","key":"10.1016\/j.mcna.2004.12.002_bib18","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.1016\/S0272-6386(00)70239-3","article-title":"Cardiovascular disease and chronic renal disease: a new paradigm","volume":"36","author":"Sarnak","year":"2000","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.mcna.2004.12.002_bib19","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1681\/ASN.V133745","article-title":"Renal insufficiency and subsequent death resulting from cardiovascular disease in the United States","volume":"13","author":"Muntner","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.mcna.2004.12.002_bib20","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1046\/j.1523-1755.2002.00270.x","article-title":"Moderate renal insufficiency and the risk of cardiovascular mortality: results from the NHANES I","volume":"61","author":"Garg","year":"2002","journal-title":"Kidney Int"},{"key":"10.1016\/j.mcna.2004.12.002_bib21","series-title":"2001 Report, volume 1: dialysis and renal transplantation. Canadian Organ Replacement Register","year":"2001"},{"key":"10.1016\/j.mcna.2004.12.002_bib22","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/S0272-6386(97)90032-9","article-title":"Prediction of early death in end-stage renal disease patients starting dialysis","volume":"29","author":"Barrett","year":"1997","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.mcna.2004.12.002_bib23","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1093\/ndt\/11.7.1277","article-title":"Outcome and risk factors for left ventricular disorders in chronic uremia","volume":"11","author":"Parfrey","year":"1996","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.mcna.2004.12.002_bib24","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S0272-6386(96)90357-1","article-title":"Prevalent left ventricular hypertrophy in the predialysis population: identifying opportunities for intervention","volume":"27","author":"Levin","year":"1996","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.mcna.2004.12.002_bib25","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/ki.1995.22","article-title":"Clinical and echocardiographic disease in patients starting end-stage renal disease therapy","volume":"47","author":"Foley","year":"1995","journal-title":"Kidney Int"},{"key":"10.1016\/j.mcna.2004.12.002_bib26","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/S1073-4449(97)70029-3","article-title":"Cardiac disease in chronic uremia: pathogenesis","volume":"4","author":"London","year":"1997","journal-title":"Adv Ren Replace Ther"},{"key":"10.1016\/j.mcna.2004.12.002_bib27","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1681\/ASN.V1341084","article-title":"Congestive heart failure in renal transplant recipients: risk factors, outcomes, and relationship with ischemic heart disease","volume":"13","author":"Rigatto","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.mcna.2004.12.002_bib28","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1046\/j.1523-1755.1998.00154.x","article-title":"Long-term evolution of cardiomyopathy in dialysis patients","volume":"54","author":"Foley","year":"1998","journal-title":"Kidney Int"},{"key":"10.1016\/j.mcna.2004.12.002_bib29","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0272-6386(99)70118-6","article-title":"Left ventricular mass index increase in early renal disease: impact of decline in hemoglobin","volume":"34","author":"Levin","year":"1999","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"10.1016\/j.mcna.2004.12.002_bib30","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1097\/00007890-200008270-00006","article-title":"Long-term changes in left ventricular hypertrophy after renal transplantation","volume":"27","author":"Rigatto","year":"2000","journal-title":"Transplantation"},{"issue":"2","key":"10.1016\/j.mcna.2004.12.002_bib31","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1046\/j.1525-139X.1999.00008.x","article-title":"Pathogenesis of cardiac disease in dialysis patients","volume":"12","author":"Parfrey","year":"1999","journal-title":"Semin Dial"},{"key":"10.1016\/j.mcna.2004.12.002_bib32","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1046\/j.1525-139X.1999.00007.x","article-title":"Hemodynamic overload in end-stage renal disease patients","volume":"12","author":"London","year":"1999","journal-title":"Semin Dial"},{"key":"10.1016\/j.mcna.2004.12.002_bib33","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/S0140-6736(98)04311-6","article-title":"Effects of intensive blood pressure lowering and low dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial","volume":"351","author":"Hansson","year":"1998","journal-title":"Lancet"},{"issue":"Suppl 2","key":"10.1016\/j.mcna.2004.12.002_bib34","first-page":"B54","article-title":"Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes","volume":"23","author":"Estacio","year":"2000","journal-title":"Diabetes Care"},{"key":"10.1016\/j.mcna.2004.12.002_bib35","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1136\/bmj.317.7160.703","article-title":"Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38","volume":"317","author":"UK Prospective Diabetes Study Group","year":"1998","journal-title":"BMJ"},{"key":"10.1016\/j.mcna.2004.12.002_bib36","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0140-6736(01)06178-5","article-title":"Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack","volume":"358","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.mcna.2004.12.002_bib37","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1001\/jama.289.19.2560","article-title":"The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure","volume":"289","author":"Chobanian","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.mcna.2004.12.002_bib38","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1053\/ajkd.2000.16225","article-title":"Preserving renal function in adults with hypertension and diabetes: a consensus approach","volume":"36","author":"Bakris","year":"2000","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.mcna.2004.12.002_bib39","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1038\/ki.1995.361","article-title":"Strict blood pressure control and progression of renal disease in hypertensive nephrosclerosis","volume":"48","author":"Toto","year":"1995","journal-title":"Kidney Int"},{"key":"10.1016\/j.mcna.2004.12.002_bib40","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1161\/01.HYP.29.2.641","article-title":"Achievement and safety of a low blood pressure goal in chronic renal disease","volume":"29","author":"Lazarus","year":"1997","journal-title":"Hypertension"},{"key":"10.1016\/j.mcna.2004.12.002_bib41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1053\/ajkd.1998.v32.pm9669419","article-title":"Antihypertensive drugs, dietary salt, and renal protection: how low should you go and with which therapy?","volume":"32","author":"Weir","year":"1998","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.mcna.2004.12.002_bib42","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1056\/NEJM199108013250501","article-title":"Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure","volume":"325","author":"The SOLVD Investigators","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.mcna.2004.12.002_bib43","doi-asserted-by":"crossref","first-page":"629","DOI":"10.7326\/0003-4819-134-8-200104170-00007","article-title":"Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial","volume":"134","author":"Mann","year":"2001","journal-title":"Ann Intern Med"},{"issue":"20","key":"10.1016\/j.mcna.2004.12.002_bib44","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","article-title":"The effect of angiotension-converting-enzyme inhibition on diabetic nephropathy","volume":"329","author":"Lewis","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.mcna.2004.12.002_bib45","doi-asserted-by":"crossref","first-page":"577","DOI":"10.7326\/0003-4819-118-8-199304150-00001","article-title":"Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients","volume":"118","author":"Ravid","year":"1993","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.mcna.2004.12.002_bib46","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1136\/bmj.315.7101.154","article-title":"Randomized, double blind, multicentre comparison of hydrochlorothiazide, atenolol, nitrendipine, and enalapril in antihypertensive treatment: results of the HANE study","volume":"15","author":"Philipp","year":"1997","journal-title":"BMJ"},{"key":"10.1016\/j.mcna.2004.12.002_bib47","doi-asserted-by":"crossref","first-page":"73","DOI":"10.7326\/0003-4819-135-2-200107170-00007","article-title":"Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease: a meta-analysis of patient-level data","volume":"135","author":"Jafar","year":"2001","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.mcna.2004.12.002_bib48","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1056\/NEJM199209033271003","article-title":"Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions","volume":"327","author":"The SOLVD Investigators","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.mcna.2004.12.002_bib49","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1056\/NEJM199209033271001","article-title":"Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction","volume":"327","author":"Pfeffer","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.mcna.2004.12.002_bib50","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.mcna.2004.12.002_bib51","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.mcna.2004.12.002_bib52","doi-asserted-by":"crossref","first-page":"616","DOI":"10.7326\/0003-4819-135-8_Part_1-200110160-00014","article-title":"American College of Cardiology, American Heart Association, American College of Physicians-American Society of Internal Medicine. Guidelines for the management of patients with chronic stable angina: treatment","volume":"135","author":"Fihn","year":"2001","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.mcna.2004.12.002_bib53","first-page":"187","article-title":"Why beta blockers should be used in heart failure","volume":"45","author":"Bhagat","year":"1999","journal-title":"Cent Afr J Med"},{"key":"10.1016\/j.mcna.2004.12.002_bib54","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1136\/bmj.320.7243.1188","article-title":"Drug treatment in heart failure","volume":"320","author":"Lonn","year":"2000","journal-title":"BMJ"},{"key":"10.1016\/j.mcna.2004.12.002_bib55","first-page":"1328","article-title":"ACC\/AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction)","volume":"28","author":"Ryan","year":"1996","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.mcna.2004.12.002_bib56","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1161\/01.CIR.0000116764.53225.A9","article-title":"Renal insufficiency and heart failure: prognostic and therapeutic implications from a prospective cohort study","volume":"109","author":"McAlister","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.mcna.2004.12.002_bib57","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/bmj.324.7329.71","article-title":"Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients","volume":"324","year":"2002","journal-title":"BMJ"},{"key":"10.1016\/j.mcna.2004.12.002_bib58","series-title":"Guidelines for antithrombotic therapy","author":"Hirsh","year":"2001"},{"key":"10.1016\/j.mcna.2004.12.002_bib59","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1053\/ajkd.2001.29275","article-title":"Cardiovascular disease in patients with chronic kidney disease: getting to the heart of the matter","volume":"38","author":"Levin","year":"2001","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.mcna.2004.12.002_bib60","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1681\/ASN.V114778","article-title":"Calcification of the aortic valve in the dialyzed patient","volume":"11","author":"London","year":"2000","journal-title":"J Am Soc Nephrol"},{"issue":"Suppl 5","key":"10.1016\/j.mcna.2004.12.002_bib61","first-page":"630","article-title":"A possible mechanism of sudden death in hypertensive left ventricular hypertrophy","volume":"5","author":"McLenachan","year":"1997","journal-title":"J Hypertens"},{"key":"10.1016\/j.mcna.2004.12.002_bib62","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1056\/NEJM200002103420603","article-title":"Retinopathy and nephropathy in patients with type I diabetes four years after a trial of intensive therapy","volume":"342","author":"The Diabetes Control and Complications Trial\/Epidemiology of Diabetes Interventions and Complications Research Group","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.mcna.2004.12.002_bib63","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","article-title":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)","volume":"352","author":"Prospective Diabetes Study UK","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.mcna.2004.12.002_bib64","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/S0140-6736(98)07037-8","article-title":"(UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)","volume":"352","author":"Prospective Diabetes Study UK.","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.mcna.2004.12.002_bib65","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1046\/j.1523-1755.2003.00860.x","article-title":"Smoking and cardiovascular outcomes in dialysis patients: the United States Renal Data System Wave 2 study","volume":"63","author":"Foley","year":"2003","journal-title":"Kidney Int"},{"key":"10.1016\/j.mcna.2004.12.002_bib66","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1001\/archinte.160.7.939","article-title":"Effect of smoking cessation on mortality after myocardial infarction: meta-analysis of cohort studies","volume":"160","author":"Wilson","year":"2000","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.mcna.2004.12.002_bib67","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0272-6386(00)70017-5","article-title":"Cigarette smoking is associated with augmented progression of renal insufficiency in severe essential hypertension","volume":"35","author":"Regalado","year":"2000","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.mcna.2004.12.002_bib68","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1046\/j.1523-1755.1998.00067.x","article-title":"Smoking as a risk factor for end-stage renal failure in men with primary renal disease","volume":"54","author":"Orth","year":"1998","journal-title":"Kidney Int"},{"key":"10.1016\/j.mcna.2004.12.002_bib69","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1097\/01.ASN.0000018401.82863.FD","article-title":"Smoking and the kidney","volume":"13","author":"Orth","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.mcna.2004.12.002_bib70","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1006\/pmed.2001.0941","article-title":"Smoking cessation and quality of life: the effect of amount of smoking and time since quitting","volume":"33","author":"Mulder","year":"2001","journal-title":"Prev Med"},{"key":"10.1016\/j.mcna.2004.12.002_bib71","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1046\/j.1445-5994.2001.00110.x","article-title":"Randomized controlled trial of two cigarette quit programmes in coronary care patients after acute myocardial infarction","volume":"31","author":"Feeney","year":"2001","journal-title":"Intern Med J"},{"key":"10.1016\/j.mcna.2004.12.002_bib72","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1046\/j.1523-1755.1999.00575.x","article-title":"Parathyroid hormone, vitamin D, and cardiovascular disease in chronic renal failure","volume":"56","author":"Rostand","year":"1999","journal-title":"Kidney Int"},{"key":"10.1016\/j.mcna.2004.12.002_bib73","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1053\/ajkd.1998.v31.pm9531176","article-title":"Association of serum phosphorus and calcium \u00d7 phosphate product with mortality risk on chronic hemodialysis: a national study","volume":"31","author":"Block","year":"1998","journal-title":"Am J Kidney Dis"},{"issue":"Suppl 3","key":"10.1016\/j.mcna.2004.12.002_bib74","first-page":"S1","article-title":"K\/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease","volume":"42","author":"National Kidney Foundation","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.mcna.2004.12.002_bib75","doi-asserted-by":"crossref","first-page":"98","DOI":"10.7326\/0003-4819-138-2-200301210-00010","article-title":"Cholesterol and Recurrent Events (CARE) Trial Investigators. Pravastatin for secondary prevention of cardiovascular events in persons with mild chronic renal insufficiency","volume":"138","author":"Tonelli","year":"2003","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.mcna.2004.12.002_bib76","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1016\/S0140-6736(03)13636-7","article-title":"MRC\/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial","volume":"361","author":"Collins","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.mcna.2004.12.002_bib77","doi-asserted-by":"crossref","first-page":"c107","DOI":"10.1159\/000074835","article-title":"Therapeutic considerations for the use of statin therapy in chronic renal disease","volume":"95","author":"Moore","year":"2003","journal-title":"Nephron Clin Pract"},{"issue":"Suppl 8","key":"10.1016\/j.mcna.2004.12.002_bib78","first-page":"13","article-title":"Anaemia and the heart: what's new in 2003?","volume":"18","author":"Foley","year":"2003","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.mcna.2004.12.002_bib79","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1097\/01.ASN.0000092138.65211.71","article-title":"Association of high serum creatinine and anemia increases the risk of coronary events: results from the prospective community-based atherosclerosis risk in communities (ARIC) study","volume":"14","author":"Jurkovitz","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.mcna.2004.12.002_bib80","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1046\/j.1523-1755.2003.00109.x","article-title":"Chronic kidney disease, anemia, and incident stroke in a middle-aged, community-based population: the ARIC Study","volume":"64","author":"Abramson","year":"2003","journal-title":"Kidney Int"},{"key":"10.1016\/j.mcna.2004.12.002_bib81","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1136\/bmj.300.6724.573","article-title":"Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis","volume":"300","author":"Canadian Erythropoietin Study Group","year":"1990","journal-title":"BMJ"},{"issue":"6 Suppl 4","key":"10.1016\/j.mcna.2004.12.002_bib82","doi-asserted-by":"crossref","first-page":"S133","DOI":"10.1016\/S0272-6386(98)70176-3","article-title":"Trends in anemia treatment with erythropoietin usage and patients outcomes","volume":"32","author":"Collins","year":"1998","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.mcna.2004.12.002_bib83","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/0277-9536(92)90129-E","article-title":"The impact of recombinant human erythropoietin on medical care costs for hemodialysis patients in Canada","volume":"34","author":"Sheingold","year":"1992","journal-title":"Soc Sci Med"},{"key":"10.1016\/j.mcna.2004.12.002_bib84","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1681\/ASN.V471455","article-title":"Effect of recombinant erythropoietin on hospital admission, readmission, length of stay and costs in dialysis patients","volume":"4","author":"Powe","year":"1994","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.mcna.2004.12.002_bib85","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/S0272-6386(12)80453-7","article-title":"Long term myocardial effects of correction of anemia with recombinant human erythropoietin in aged patients on hemodialysis","volume":"19","author":"Martinez-Vea","year":"1992","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.mcna.2004.12.002_bib86","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/0272-6386(95)90122-1","article-title":"Health-related quality of life associated with recombinant human erythropoietin therapy for predialysis chronic renal disease patients","volume":"25","author":"Revicki","year":"1995","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.mcna.2004.12.002_bib87","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1056\/NEJM199808273390903","article-title":"The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin","volume":"339","author":"Besarab","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.mcna.2004.12.002_bib88","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1046\/j.1523-1755.2000.00289.x","article-title":"Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy","volume":"58","author":"Foley","year":"2000","journal-title":"Kidney Int"},{"key":"10.1016\/j.mcna.2004.12.002_bib89","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1097\/01.ASN.0000102471.89084.8B","article-title":"Effects of early and late intervention with epoetin alpha on left ventricular mass among patients with chronic kidney disease (stage 3 or 4): results of a randomized clinical trial","volume":"15","author":"Roger","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.mcna.2004.12.002_bib90","unstructured":"Foley RN, Parfrey PS, Wittreich BH, et al. The effect of higher haemoglobin levels on left ventricular cavity volume in patients starting haemodialysis: a blinded, randomised, controlled trial in 596 patients without symptomatic cardiac disease [abstract]. ERA-EDTA, Lisbon, Portugal, 2004. Available at: http:\/\/abstracts 2view.com\/era\/authorindex.php. Accessed January 26, 2005."},{"key":"10.1016\/j.mcna.2004.12.002_bib91","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/S0272-6386(96)90383-2","article-title":"Excess morbidity in patients starting uremia therapy without prior care by a nephrologist","volume":"28","author":"Ifudu","year":"1996","journal-title":"Am J Kidney Dis"},{"issue":"12 Suppl","key":"10.1016\/j.mcna.2004.12.002_bib92","first-page":"S124","article-title":"Improving access patency: pre-end-stage renal disease strategies","volume":"9","author":"Schwab","year":"1998","journal-title":"J Am Soc Nephrol"}],"container-title":["Medical Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002571250400207X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002571250400207X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,7,8]],"date-time":"2021-07-08T23:28:27Z","timestamp":1625786907000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002571250400207X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,5]]},"references-count":92,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2005,5]]}},"alternative-id":["S002571250400207X"],"URL":"https:\/\/doi.org\/10.1016\/j.mcna.2004.12.002","relation":{},"ISSN":["0025-7125"],"issn-type":[{"value":"0025-7125","type":"print"}],"subject":[],"published":{"date-parts":[[2005,5]]}}}